Trim AMGN 15-20% at $413 targeting 80-85% benchmark weight; $395 hard stop, $400 PT, 2-3 week horizon to Q3 2026 earnings
Underweight rating maintained with measured 15-20% trim at $413, targeting 80-85% benchmark weight. This sizing honors the 9/21 anti-preemption cap while acknowledging macro deterioration and multiple-compression risk. $395 hard stop (1.1 ATR below entry) is validated by 10/01 ATR anchoring lesson. $400 PT sits below spot to reflect directional concern without explicit short framing (avoiding 9/29 bias-leakage failure). Pre-committed upgrade triggers: Q3 beat-and-raise or volume-confirmed close >$425 (→ upgrade to Hold). Downgrade trigger: miss/cut on guidance (→ Sell, $375 PT). Rejecting: (a) full Sell (forfeits 2.5% dividend carry and re-engagement optionality); (b) 30-50% trim (violates 9/21 cap); (c) full Hold (ignores worsening macro/multiple risk since 10/06); (d) 25-35% trim (crosses into alpha-translation gap per 10/05 lesson). Technical recovery (50 SMA reclaimed, MACD expanding, RSI 54) provides partial offset justifying measured Underweight vs. pure Hold repeat.
| Position | Action |
|---|---|
| Current position >80-85% benchmark weight | Trim 15-20% of existing AMGN exposure |
| Trim executed at $413 (current spot) | Target residual position at 80-85% benchmark weight |
| Position sized 25-30%+ of current exposure | REJECTED — exceeds 9/21 anti-preemption cap for pre-binary trimming |
AMGN is mispriced relative to its earnings power, pipeline optionality, and accelerating deleveraging story — the 16.88x forward P/E and 10% revenue growth rate are being masked by a noisy chart and debt fears that ignore the $1B/quarter net debt reduction and 5x EBITDA interest coverage.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $407.81 | bullish |
| 50 SMA | $410.14 | neutral |
| 200 SMA | $362.29 | bullish |
| RSI (14) | 54.19 | neutral |
| MACD Line | 0.79 | bullish |
| MACD Signal | 0.12 | bullish |
| MACD Histogram | +0.67 | bullish |
| Bollinger Upper Band | $431.34 | neutral |
| Bollinger Middle Band (20 SMA) | $399.06 | neutral |
| Bollinger Lower Band | $366.78 | neutral |
| ATR (14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Volume-confirmed close above $425
Then: Upgrade from Underweight to Hold
↩ rebuts: “Bear's value trap narrative”
EV: +19.5% · concedes: MariTide success is not required for the bull case to work — it is upside on top of upside; The September crash may have had a legitimate fundamental catalyst, but the recovery happened regardless; The breakout above $425 is unconfirmed and dependent on Q3 earnings delivery; IRA drug-price negotiation remains a structural overhang on biologic pricing power
AMGN's Q2'26 EPS growth is cosmetic (tax normalization and one-time items), organic growth is masked by the Horizon acquisition, the PEG ratio of 2.43 makes it expensive relative to growth, the $57B debt load faces refinancing risk at today's 5%+ rates, and the technical picture shows distribution at $425 rather than a coiled spring—the probability-weighted expected return is -5.4%.
EV: -5.4% · concedes: Q2'26 was the strongest quarter and IS worth something—the bull is correct that the Q2'26 result is genuine; AMGN is deleveraging (net debt down $4.9B over five quarters), interest coverage of 5x EBITDA is adequate, dividend is not at immediate risk; The long-term uptrend is technically intact with 200 SMA at $362; The MACD histogram did turn positive, showing some short-term momentum
→ vs neutral: Neutral analyst's 'cautiously bullish but unconfirmed' thesis confuses mean reversion bounce with new uptrend; RSI at 54 is absence of signal, not a buy signal; momentum indicators are lagging by definition and similar technical picture existed before September 8 crash that saw 16% single-week drop; forward multiple attractiveness ignores biosimilar erosion and pipeline execution risks
→ vs conservative: FCF floor at $8.65 billion and deleveraging story are credit metrics, not equity catalysts; AMGN being repriced by market not held hostage by balance sheet; value trap error of catching falling knife with balance sheet rather than waiting for catalyst; trim of 30-50% too timid when risk-reward is asymmetric at 16.88x forward P/E in rising rate environment
| $10.27 |
| neutral |
| VWMA | $404.32 | bullish |
| Price Close | $413.08 | neutral |
| Gap 10 EMA to 50 SMA | ~$2.33 | neutral |
Support: 366.78 · 375.65 · 393.95 · 402.6 · 400 | Resistance: 423 · 426 · 431.34 · 432 · 444
AMGN technical analysis dated October 7, 2026 shows a cautious recovery from a September crash (~$444 to ~$376). The stock has reclaimed short and medium-term moving averages with constructive momentum indicators (RSI 54.19, MACD histogram +0.67), but faces stiff resistance at $423–$431 and remains ~7% below the pre-crash high. The long-term uptrend is intact above the 200 SMA at $362.29. A confirmed close above $425 would unlock targets toward $444; failure to break $425 likely keeps price range-bound between $400–$425. The final recommendation is HOLD.
Market Capitalization
$223.3 billion
Trailing P/E
25.66x
Forward P/E
16.88x
PEG Ratio
2.43
Price/Book
19.11x
EPS (TTM)
$16.10
Forward EPS
$24.47
Dividend Yield
2.50%
Beta
0.41
52-Week High
$447.03
52-Week Low
$288.00
50-Day Average
$410.55
200-Day Average
$365.31
Revenue (TTM)
$38.09 billion
Net Income (TTM)
$8.74 billion
Free Cash Flow (TTM)
$8.65 billion
Gross Margin
~72%
Operating Margin
35.5%
Net Profit Margin
23.0%
EBITDA (TTM)
$17.27 billion
EBITDA Margin
~45%
Return on Equity
91.5%
Return on Assets
8.67%
Debt/Equity
490%
Interest Coverage (EBITDA)
~5x
Interest Expense (TTM)
~$2.7B
Cash & Equivalents (Q2'26)
$13.99 billion
Total Debt (Q2'26)
$57.30 billion
Net Debt (Q2'26)
$43.32 billion
Stockholders' Equity (Q2'26)
$11.69 billion
Total Assets (Q2'26)
$95.64 billion
Current Ratio (Q2'26)
1.37
Goodwill
$18.67 billion
Other Intangibles (Q2'26)
$20.49 billion
Tangible Book Value
$-27.5 billion
Working Capital (Q2'26)
$9.46 billion
Depreciation & Amortization
~$1.1B/quarter
CapEx (TTM)
~$2.3 billion
Operating Cash Flow (TTM)
~$12.5 billion
Q2'26 Revenue
$10.05 billion
Q2'26 Revenue YoY Growth
+10%
Q2'26 Gross Profit
$7.24 billion
Q2'26 Operating Income
$3.51 billion
Q2'26 Net Income
$2.38 billion
Q2'26 Diluted EPS
$4.37
Q2'26 EPS YoY Growth
+65%
Q2'26 Operating Cash Flow
$4.00 billion
Q2'26 Free Cash Flow
$3.49 billion
Q2'26 Dividends Paid
$1.36 billion
Net Debt Change (5 quarters)
-$4.9 billion
Strengths
Concerns
Amgen is a high-quality, cash-generative biotech with accelerating earnings, a deleveraging balance sheet (net debt down $4.9B to $43.3B in 5 quarters), and a low-beta defensive profile trading at a reasonable forward P/E of 16.9x with ~52% expected EPS growth. Q2'26 demonstrated strong momentum with $10.05B revenue (+10% YoY) and $4.37 EPS (+65% YoY), while TTM free cash flow of $8.65B supports the 2.5% dividend yield. Principal overhangs include $57.3B total debt, patent-cliff exposure on Prolia/Enbrel, and binary pipeline risk in obesity (MariTide), making the stock suitable as a core healthcare holding rather than a high-beta trade.
Macro: The macro environment has shifted markedly against defensive large-cap pharma: long-duration rates have surged with the 10Y Treasury at its highest since 2002 and posting the biggest monthly gain since 2022, while Fed officials continue warning inflation is too high and prediction markets price 96% probability of zero Fed rate cuts in 2026. Equity indices are at record highs on tech-led strength despite the rate surge, recession odds remain low near-term (6% by end-2026) but rise medium-term (34% by end-2027), and Iran conflict represents a new inflation driver beyond energy relevant to biologics manufacturing costs. The disconnect between surging long yields and risk-on equity behavior is unusual and historically pressures long-duration assets like healthcare/growth names on the multiples side.